Navigation Links
Novasys Medical Secures $49.5 Million in Series D Financing to Expand Commercialization of Its Renessa(R) Treatment for Incontinence in Women
Date:5/15/2008

NEWARK, Calif., May 15 /PRNewswire/ -- Novasys Medical, Inc., a developer of innovative therapies in women's health, announced today that it has secured $49.5 million in Series D preferred stock financing. The round was led by Versant Ventures, with ThreeArch Partners and Skyline Ventures also participating as new investors. The round also included participation by existing investors Affinity Capital Management, Alloy Ventures, Delphi Ventures, GBS Venture Partners, INVESCO Private Capital, JP Morgan Partners (managed by Panorama Capital), and ONSET Ventures.

"We are very pleased that Versant, ThreeArch and Skyline, three of the best known and respected venture capital firms in the Silicon Valley, have joined our top-tier group of existing investors," said Debra Reisenthel, President and CEO of Novasys Medical. "This financing will enable the Company to further its efforts to bring the innovative Renessa(R) non-surgical treatment to women suffering from stress urinary incontinence (SUI). The funds will allow us to continue our clinical studies as well as secure reimbursement for the Renessa procedure."

Beckie Robertson, Managing Director with Versant Ventures and new member of Novasys' Board of Directors, remarked, "Novasys Medical's Renessa System represents one of the most exciting technologies in women's health in recent years. Women with SUI are looking for alternatives to surgery and conservative therapies such as Kegel exercises. The limited availability of effective non-surgical options has resulted in a huge unmet need and Renessa is uniquely positioned to address that need." Rich Lin has joined the Board of Directors for ThreeArch Partners and Steve Sullivan has joined the Board representing Skyline Ventures.

Female Stress Urinary Incontinence

SUI is the involuntary leakage of urine associated with laughing, coughing, sneezing and recreational activities. The condition is caused by a variety of factors, most commonly child
'/>"/>

SOURCE Novasys Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. BioMS Medical announces its intention to renew a normal course issuer bid
6. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
7. ATS Medical Expands Open Pivot Heart Valve Offerings
8. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
9. Globus Medical Announces Record 2nd Quarter 2007 Results
10. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
11. China Medical Technologies Reports First Quarter Financial Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)... , CALGARY, Dec. 2 /PRNewswire-FirstCall/ - On...y") (TSX:ONC; NASDAQ: ONCY ) announced today that ...ffering, the underwriters have exercised in full t...onal 637,500 units. Each unit is comprised of one ...rrant, and was sold at a price of US$3.00 per unit...
(Date:12/2/2009)... , JERUSALEM, Israel, December 2 /PRNewswi...tudy evaluating the preclinical (animal study) saf...ombines technology from Weill,Cornell Medical Coll...l to,treat inherited anemias such as Cooley,s Anem...of technologies to expand, ex vivo,populations of...
(Date:12/2/2009)...QUEBEC CITY, Dec. 2 /PRNewswire-FirstCall/ - AEter...Company"), a global biopharmaceutical company focu...nced that the U.S. Food and Drug Administration (F...pany,s PI3K/Akt pathway inhibitor compound, perifo...ractory multiple myeloma. Keryx Biopharmaceuticals...
(Date:12/1/2009)... Dr. Kerry Solomon announced that he ...nched his redesigned website at www.DrKerrySolomo...Group. Dr. Solomon is a proven LASIK, lens implan...sionally recognized for his substantial contributi... a member of Trusted LASIK Surgeons, which screens...
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 2Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 4Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 5Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 6
...ic for IBD with Novel Mode of Action , , MOUNTAIN... announced that data from the company,s PROTECT-1 ...n in Crohn,s disease Trial) Phase II/III clinical ...th moderate-to-severe Crohn,s disease will be pres...stive Disease Week (DDW) meeting. Traficet-EN is ...
...-FirstCall/ - Neptune Technologies & Bioressou...day reports its consolidated financial results for...reports record revenues, EBITDA(1) and first-time ...ruary 28, 2009. Neptune and Acasti Pharma amended ...dated operating results for its nutraceutical busi...
...m AppExchange saves time for reprint buyers by int...om within Salesforce CRM , , SANTA MONICA, Calif....w company, today announced the availability of R...esforce.com . Built using the Force.com platform,... service that enables buyers in healthcare marketi...
Other Biology Technology:ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 2ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 3ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 4ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week 5Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business 2Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business 3Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business 4Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business 5Reprints Desk Medical Reprint Service Now Available to Life Science Professionals on the Force.com AppExchange 2Reprints Desk Medical Reprint Service Now Available to Life Science Professionals on the Force.com AppExchange 3
(Date:12/2/2009)..., PHILADELPHIA Assurance of a cancer-free status...m computerized tomography (CT) lung-cancer screeni...archers wrote in a study published in Cancer Epid...he American Association for Cancer Research. The D... , These findings should negate widespread conce...
(Date:12/2/2009)..., HOBOKEN - A team comprised of undergraduate stu...rded top honors in a national poster contest hoste...Engineering (ISPE). , The annual contest highlig... held last month at the ISPE Annual Meeting in San...luation of a Posterior Criciate Ligament Tensionin...
(Date:12/2/2009)..., The Manpei Suzuki Diabetes Foundation is please... Prize: Donald F. Steiner, MD, A. N. Pritzker Dist...of Medicine and Biochemistry and Molecular Biology...as inaugurated in 2008 to commemorate the 15th ann... honoring those who have enlightened researchers i...
Breaking Biology News(10 mins):Repeat negative CT scan for lung cancer does not encourage ex-smokers to resume the habit 2New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 1New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 2New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 3New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 4New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 5New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 6New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 7New HIV Study Shows That Large Numbers of Women and People of Color Can Be Successfully Enrolled In U S HIV Clinical Studies 52096 8Elder Boom Will Be Felt Worldwide 52094 1Elder Boom Will Be Felt Worldwide 52094 2Mylan Declares Quarterly Preferred Stock Dividend 52089 1
...to imitate sounds that are not typical of their sp...al learning in a non-primate terrestrial mammal. T...supports the idea that vocal learning is important...mong animals that separate and reunite over time, ...Researchers from the Amboseli Trust for Elephants ...
...ance sensitivity to chemical,detection by factor o...ings of the National Academy of,Science finds that...hance chemical sensing by as much as 10 billion ti...tive at Raman scattering than,traditional methods....mall fraction of the light,interacts in such a way...
...asdaq: NGEN), developer of advanced diagnostic pro...ent No. 6,867,048, "Multiplexed Active Biologic Ar...,048 patent relates to a method of addressing one ...le rows and columns of a microarray. The patent al...ltage associated with each electrode in a local me...
Other Biology News:Elephants imitate sounds as a form of social communication 2Study shows nanoshells ideal as chemical nanosensors 2Nanogen Issued Patent for Electronic Microarray With Memory 2
Silencer Pre-designed siRNA, HPLC purified, annealed from Ambion
...pidly and reliably amplify unknown genomic DNA us...hassle-free, ready-to use components, at an extrao...ents are provided in each kit. The Genome Walking ... of genomic DNA, isolating promoter and regulatory...
Rabbit Anti-Yaf9 Polyclonal Antibody, Unconjugated from Abcam
Bovine Calf Serum - 500mL from GeneTex
Biology Products: